(Q42999619)

12 November 2017

Duration of peginterferon therapy in acute hepatitis C: a randomized trial (English)

1 reference

12 November 2017

1 reference

Khalifa E Khalifa

6

0 references

Sanaa M. Kamal

object named as

Sanaa M Kamal

1

0 references

Nezam Afdhal

object named as

Nezam H Afdhal

11

0 references

author name string

Khairy N Moustafa

2

1 reference

12 November 2017

Jason Chen

3

1 reference

12 November 2017

Jutta Fehr

4

1 reference

12 November 2017

Azza Abdel Moneim

5

1 reference

12 November 2017

Leila A El Gohary

7

1 reference

12 November 2017

Amr H Ramy

8

1 reference

12 November 2017

Mohamed A Madwar

9

1 reference

12 November 2017

Jens Rasenack

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

12 November 2017

1 reference

12 November 2017

43

1 reference

12 November 2017

923-931

1 reference

12 November 2017

5

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

12 November 2017

1 reference

The epidemiology of acute and chronic hepatitis C.

21 January 2018

1 reference

7 January 2021

1 reference

7 January 2021

Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients

1 reference

7 January 2021

Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42 years of marriage.

1 reference

7 January 2021

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

7 January 2021

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

1 reference

7 January 2021

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

1 reference

7 January 2021

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

7 January 2021

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

1 reference

7 January 2021

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

1 reference

7 January 2021

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

1 reference

7 January 2021

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

1 reference

7 January 2021

Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response.

1 reference

7 January 2021

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

1 reference

7 January 2021

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

1 reference

7 January 2021

Long-term follow-up after successful interferon therapy of acute hepatitis C.

1 reference

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

1 reference

7 January 2021

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21197

1 reference

12 November 2017

1 reference